Shares of Rallybio Corp. (RLYB) are up 71% on Thursday following the announcement of a partnership with Johnson & Johnson (JNJ) aimed at advancing therapeutic approaches to mitigate the risk of fetal and neonatal alloimmune thrombocytopenia also known as FNAIT.
RLYB is trading on the Nasdaq at $2.79, up 71.47% or $1.16 per share. It has traded between $1.22 and $9.14 in the past 52-week period.
Additionally, Rallybio secured a $6.6 million equity investment from Johnson & Johnson Innovation.
The company is working on RLYB212, a human monoclonal anti-HPA-1a antibody designed to prevent FNAIT by halting the production of alloantibodies in expecting mothers.
Rallybio intends to commence a Phase 2 trial for RLYB212 in the latter part of 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.